Clinical Trial

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).
Protocol Amendment History 3 changes
notable Trial sites expanded: 37 -> 43 locations 2026-07-25
notable Trial sites expanded: 24 -> 32 locations 2026-05-01
notable Trial sites expanded: 18 -> 24 locations 2026-04-09
Trial Details
NCT Number NCT07159841
Lead Sponsor Crinetics Pharmaceuticals Inc.
Conditions Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Enrollment 153 participants
Start Date 2026-01-22
Primary Completion 2030-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-12